Overview


According to FutureWise analysis, the market for Addison's Disease Treatment is expected to grow at a CAGR of 10.70% over the forecast period of 2023-2031. 

Primary adrenal insufficiency, another name for Addison's disease, is a rare chronic condition in which the adrenal glands, located at top of the kidneys, fail to generate enough cortisol and, occasionally, aldosterone. These hormones control several biological processes, including blood pressure regulation, electrolyte balance, and the body's reaction to stress. Adrenal gland malfunction or injury is the leading cause of Addison's disease. Inadvertent destruction of adrenal tissue can happen due to autoimmune reactions, where the body's immune system wrongly targets and destroys it. Infections, including tuberculosis or fungal infections, specific drugs, bleeding into the adrenal glands, or genetic factors, are examples of additional reasons. Clinical evaluation, reviewing medical history, and laboratory tests are essential for the diagnosis of Addison's disease. Laboratory blood tests are required to measure cortisol and adrenocorticotropic hormone (ACTH) levels, providing insight into the functioning of the adrenal glands. Additional diagnostic procedures, such as ACTH stimulation tests or imaging studies, are conducted to determine the underlying cause of adrenal insufficiency.

After diagnosis, the primary treatment for Addison's disease must be hormone replacement therapy, which aims to compensate for the deficient hormones in the body. Typically, this involves the administration of oral glucocorticoids, such as hydrocortisone or prednisone, and mineralocorticoids, like fludrocortisone, to restore cortisol and aldosterone levels. Dosages are regularly adjusted based on individual requirements, stress levels, and overall health conditions. The prevalence is 0.6 per 100,000 people annually. Addison’s disease affects somewhere between 4 and 11 individuals out of every 100,000 individuals at any particular moment. The typical age of symptomatic presentation in adults is between 30 and 50. Women are more likely to be diagnosed with it.

FutureWise Market Research has published a report that provides an insightful analysis of Addison's Disease Treatment Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes the stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, Addison's Disease Treatment Market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition to providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organization to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  •  Pfizer Inc.
  •  Boehringer Ingelheim GmbH
  •  ViroPharma
  •  Tocris Bioscience
  •  GlaxoSmithKline plc
  •  Merck KGaA
  •  Lupin Pharmaceuticals, Inc.
  •  Shire
  •  Abbott Laboratories
  •  Amgen

(Note: The list of the major players will be updated with the latest market scenario and trends)

While Addison's disease is considered a rare condition, there is a growing recognition of its prevalence. Improved diagnostic techniques and increased awareness among healthcare professionals have led to a higher detection rate. The rising number of diagnosed cases of Addison's disease drives the demand for treatment options. The development of advanced diagnostic technologies has facilitated early detection and accurate diagnosis of Addison's disease. These technologies include blood tests to measure hormone levels, genetic testing to identify specific gene mutations, and imaging studies to evaluate adrenal gland function and structure. Improved diagnostics contribute to timely intervention and treatment initiation. Advances in drug delivery systems and technologies are driving Addison's disease treatment market. Efforts are being made to develop more patient-friendly drug formulations, such as extended-release medications or implantable devices, that can provide sustained hormone replacement therapy. These advancements enhance patient compliance, convenience, and overall treatment outcomes. Rise in the prevalence of personalized therapy in endocrinology and rare disorders domain is also responsible to drive the market's growth. The identification of specific genetic mutations or changes that affect the onset and progression of Addison's disease may be made possible through genetic testing and molecular profiling. This data can help in the customization of treatment programs and can eventually result in targeted therapy. However, long-term hormone replacement therapy for Addison's disease can be expensive for patients, especially in regions with poor healthcare systems or substantial out-of-pocket expenses. The requirement for ongoing medication and frequent observation increases the overall treatment cost. Access to therapy may be restricted due to affordability issues, which adversely affect the market. Due to the rarity of Addison's disease, there is a lack of endocrinologists or other specialists with the necessary knowledge to treat the condition. Lack of access to skilled healthcare experts may lead to inadequate treatment and insufficient disease management thereby limiting the market growth.

By Type Of Drug Class

  •  Glucocorticoid
    •  Hydrocortisone
    •  Dexamethasone
    •  Prednisone
  •  Mineralocorticoid
    •  Fludrocortisone

By Distribution Channel

  •  Hospital Pharmacy
  •  Retail Pharmacy
  •  E-commerce

By End-Use

  • Research Laboratories and Institutes
  • Hospitals and Diagnostic Laboratories
  • Cell Banks
  • Biotechnology and Biopharmaceutical companies

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa

This market research report also emphasizes on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. Several driving factors are responsible for the dominance of North America which include developed healthcare infrastructure, advanced diagnostic tools, and high professional awareness. Additionally, autoimmune disorders are more prevalent in the region, which may explain why there is a greater need for Addison's disease treatment. CDC (Centers for Disease Control and Prevention) estimates that 8,300 cases of TB will be reported (provisional) in the United States year 2022, or 2.5 cases per 100,000 people.

  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants

  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Addison's Disease Treatment Market By Type of Drug Class, By Distribution Channel, and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Addison's Disease Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Addison's Disease Treatment Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Addison's Disease Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Addison's Disease Treatment Market, By Type Of Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Glucocorticoid
         1.1. Hydrocortisone
         1.2. Dexamethasone
         1.3. Prednisone
        2. Mineralocorticoid
         2.1. Fludrocortisone

  • 8.   Global Addison's Disease Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. E-commerce

  • 9.  Global Addison's Disease Treatment Market, By End-Use Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Research Laboratories and Institutes
        2. Hospitals and Diagnostic Laboratories
        3. Cell Banks
        4. Biotechnology and Biopharmaceutical companies

  • 10.   North America Addison's Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Addison's Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Addison's Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Addison's Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Addison's Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Boehringer Ingelheim GmbH
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. ViroPharma
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Tocris Bioscience
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline plc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merck KGaA
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Lupin Pharmaceuticals, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Shire
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Abbott Laboratories
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Amgen
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Addison Disease Testing Market

Read More
Partner

Our Clients